UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

UMass Chan Medical School has received $2.2 million from a nonprofit patient-advocacy organization to contract with Andelyn Biosciences to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.

Please click here to be taken to the external linkDownload

News & Press Releases

Press Release

October 9, 2024

Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16) Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16)
Press Release

August 6, 2024

Andelyn Biosciences Expands AAV Curator™ Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and HarvardAndelyn Biosciences Expands AAV Curator™ Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and Harvard
Press Release

July 10, 2024

Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne SyndromeAndelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne Syndrome
News

June 11, 2024

UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne SyndromeUMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome
View All News & Press Releases
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept